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Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact.
Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine
such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related
peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to
be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we
review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking
CGRP have been developed: small molecule CGRP receptor antagonists (gepants), and monoclonal antibodies,
targeting either CGRP or the CGRP receptor. Several trials have been conducted to test the efficacy and safety of
these drugs. In general, a superior efficacy compared to placebo has been shown, especially with regards to the
antibodies. In addition, the efficacy is in line with other currently used prophylactic treatments. The drugs have also
been well tolerated, except for some of the gepants, which induced a transient increase in transaminases. Thus,
blocking CGRP in migraine patients is seemingly both efficient and well tolerated. However, CGRP and its receptor
are abundantly present in both the vasculature, and in the peripheral and central nervous system, and are involved
in several physiological processes. Therefore, blocking CGRP may pose a risk in subjects with comorbidities such as
cardiovascular diseases. In addition, long-term effects are still unknown. Evidence from animal studies suggests that
blocking CGRP may induce constipation, affect the homeostatic functions of the pituitary hormones or attenuate
wound healing. However, these effects have so far not been reported in human studies. In conclusion, this review
suggests that, based on current knowledge, the pros of blocking CGRP in migraine patients exceed the cons.
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Migraine is a highly prevalent and disabling disorder for
which treatment options are still inadequate. The under-
lying pathophysiology is largely unknown, but calcitonin
gene-related peptide (CGRP) most likely plays an im-
portant role. The first time CGRP was hypothesized to
be involved in migraine was in 1985 [1]. This hypothesis
was later supported by the finding of CGRP release dur-
ing acute migraine attacks and the subsequent* Correspondence: mariedeen85@gmail.com
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the Creative Commons license, and indicate ifdemonstration of normalization of CGRP levels in mi-
graine patients after efficacious sumatriptan treatment
[2]. In animal studies, triptans also inhibit the release of
CGRP [3]. Evidence for a causative role of CGRP in mi-
graine came from a study showing that intravenous
provocation with CGRP induces migraine-like attacks in
migraine patients [4]. This led to focus on this peptide
and its receptor as a possible target for new migraine
therapies.
CGRP and its receptor are expressed in both the periph-
eral and the central nervous system (CNS), including the
trigeminovascular pathways. More than 30 years ago CGRP
was demonstrated in trigeminal ganglion (TG) pseudouni-
polar neurons [5]. These neurons connect cranial structures
to the central nervous system at the lower brainstem,is distributed under the terms of the Creative Commons Attribution 4.0
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spinal cord at C1-C2 [6]. In the peripheral trigeminovascu-
lar system, as well as in the TG, CGRP is located in about
50% of the neurons and in unmyelinated Cfibers, whereas
the CGRP receptor elements are expressed in about 40% of
the TG neurons and in myelinated A-fibers, which connect
the PNS with the CNS [7, 8]. In humans, CGRP is present
in two isoforms, α-CGRP and β-CGRP, where α-CGRP is
most abundantly found in primary spinal afferents from
sensory ganglia, whereas β-CGRP is mainly found in the
enteric nervous system [6]. The CGRP receptor consists of
three subunits: receptor activity-modifying protein 1
(RAMP1), calcitonin-like receptor (CLR) and receptor
component protein (RCP) [9]. As well as playing a role in
cranial nociception [10], CGRP is a potent general arterial
vasodilator. At peripheral synapses, CGRP released from
trigeminal terminals results in vasodilation via CGRP re-
ceptors on the smooth muscle cells of meningeal and cere-
bral blood vessels [8, 11]. CGRP and its receptor are also
located in the cardiovascular system where they are as-
sumed to exert a protective role [9, 12].
The first designer drug able to competitively block the
effect of CGRP was olcegepant [13]. This nonpeptide
CGRP-receptor antagonist showed high efficacy but had
a low oral bioavailability [14]. This led, however, to the
synthesis of several other small molecule CGRP receptor
antagonists. This class was later called the gepants.
Though promising with regards to efficacy, further de-
velopment of some of the gepants was discontinued due
to liver toxicity upon repeated exposure [15]. Encour-
aged by the efficacy of blocking CGRP for the treatment
of migraine, monoclonal antibodies able to block either
CGRP or its receptor were developed and tested in sev-
eral preclinical modalities [16, 17]. The antibodies are
designer drugs that are highly specific for the target but
about 500 times the size of gepants or triptans [6]. They
have been designed for prophylactic use in frequent epi-
sodic and chronic migraine. In this review, we will dis-
cuss the pros and cons of blocking CGRP in migraine
patients. We will review the efficacy and safety of already
tested drugs and compare it to the efficacy and safety of
topiramate, a widely-used migraine prophylactic. Add-
itionally, we will review the possible consequences of
blocking CGRP based on findings from animal studies.
Lastly, we will discuss other concerns such as long-term
use and cost of the treatment.
Efficacy of CGRP (receptor) blockade: Evidence from
double-blind, placebo-controlled trials
In 2004, a proof-of-concept study showed that intravenous
olcegepant was effective in the acute treatment of mi-
graine [18]. Since then, five other gepants have been tested
for the acute treatment of migraine [19–33]. Figure 1 pro-
vides an overview of the efficacy data for these agents. Allgepants were significantly better than placebo at achieving
their primary outcome at adequate doses: pain freedom or
relief at 2 h. Only one study, a study on safety in coronary
patients, could not demonstrate difference in pain free-
dom at 2 h after telcagepant; however, only 165 of the
planned 400 patients were included, reducing the statis-
tical power of this study [27].
Five of these studies also included a comparison to a
triptan [19, 21, 26, 29, 30]. In one of these studies, telca-
gepant showed a numerically higher efficacy than riza-
triptan with regards to sustained pain relief [29]. In
other trials, the efficacy of telcagepant, BI44370 and
rimegepant showed no significant difference to that of
zolmitriptan (5 mg), eletriptan (40 mg) and sumatriptan
(100 mg), respectively [21, 26, 30]. In one large study,
assessing the long-term safety of telcagepant, 19,820 at-
tacks were treated with telcagepant and 10,981 attacks
with rizatriptan. For two endpoints, pain freedom and
pain relief at 2 h, rizatriptan was superior compared to
telcagepant (OR <1 in favor of rizatriptan. OR (95% CI):
0.58 (0.45, 0.75) and 0.70 (0.55, 0.89), respectively). For
all other pre-specified efficacy outcome measurements,
no difference was found between the efficacy of telcage-
pant and rizatriptan at 2 h [19].
Telcagepant has also been tested as prophylactic treat-
ment of episodic migraine [25, 28]. The first of these studies
was terminated early due to adverse events and the pre-
specified analyses could not be performed. However, post-
hoc analysis showed telcagepant to be effective at four
weeks in reducing migraine days [25]. In the second study,
in a population of patients with perimenstrual migraine, ad-
ministration of telcagepant in the perimenstrual period did
not result in a significant reduction in mean monthly head-
ache days, which was the primary endpoint [28]. There was
a reduction of mean monthly on-drug headache days, but
the reliability of this analysis is questionable, since no
correction for multiple comparisons was done.
Antibodies against CGRP or the CGRP receptor have
been tested as prophylactic treatment of episodic and
chronic migraine. To date, four agents have been studied
in six clinical studies [31, 32, 34–37]. Figure 2 provides
an overview of the efficacy data of the studies where re-
duction in migraine days was the primary endpoint. All
monoclonal antibodies showed a significant reduction in
their primary endpoint, either mean change from base-
line in monthly migraine days (5 studies) or mean
change in headache hours from baseline (1 study). These
agents had an additional reduction over placebo of be-
tween 1 and 2.8 migraine days per month (when not
considering the inefficacious lower doses of erenumab).
In the study in chronic migraine, where change in head-
ache hours was the primary outcome (data not included
in the figure), the additional reduction over placebo was
22.7 and 30.4 h per month for the two doses tested [37].
Fig. 1 Efficacy of gepants in the acute treatment of migraine. Bars indicated with * represents statistically significant values compared to placebo (p < 0.05)
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Fig. 2 Efficacy of monoclonal antibodies in the preventive treatment of migraine. Bars indicated with * represents statistically significant values
compared to placebo (p < 0.05). (1) had change in mean monthly migraine days from baseline to weeks 5–8 as the primary endpoint. All other studies
had change in monthly migraine days from baseline to weeks 9–12 of the 12-week double-blind treatment phase as the primary endpoint. In (1) the
drug/placebo was administered intravenously. In all other studies, the drug/placebo were given subcutaneously. (2) is on chronic migraine
patients. All other studies are on episodic migraine patients
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who had 5 to 14 migraine days per month at baseline,
experienced no migraine days during the 12 week study
period, versus no patients in the placebo group [34]. In
another study, 31 of 98 (32%) patients reporting 4 to 15
migraine days at baseline had a 100% response (defined as
a 28-day migraine free period over the 12-week treatment
period). In the placebo group, only 18 of 104 (17%) of pla-
cebo patients had a 100% response [35]. No other studies
reported on the 100% responder rate. Although these data
seem interesting, they come from post-hoc analyses and
so their significance remains unclear.
The data from these 20 studies provides robust and
consistent evidence for a crucial role of CGRP in mi-
graine pathophysiology and a high efficacy of blocking
CGRP as a prophylactic treatment.Is blocking CGRP as or more efficient than current
preventative treatments?
Current preventative treatment options for migraine in-
clude antihypertensive drugs, antidepressants and anti-
epileptic medication. In contrast to CGRP (receptor)
blockers, these have all been developed for diseases
other than migraine and it is estimated that less than
50% of patients on prophylactics experience a 50% re-
duction in their monthly attack frequency [38].
Topiramate was proven efficient as a preventative
treatment of episodic migraine after positive results from
three randomized, multi-center, placebo-controlled stud-
ies. Thus, topiramate is currently recommended as a
level A medication for prevention of episodic migraine
with established efficacy (≥ 2 Class I trials) in the 2012
AHS/AAN guidelines [39]. Here, we review so far pub-
lished data from Phase III studies of the monoclonalantibodies [40–43] in relation to pivotal studies on topir-
amate [44–48] in episodic and chronic migraine.
In three phase III studies, including over 1500 pa-
tients, topiramate 100 mg/d significantly reduced the
number of monthly migraine days compared to placebo
(reduction of monthly migraine days about −1.8 to −2.6
for topiramate vs. -1.0 to −1.3 for placebo). The ≥50%
responder rates were also significantly higher for topira-
mate (37–54% vs. 22–23%, respectively) [44–46]. In the
so far available data from Phase III studies of CGRP
(receptor) antibodies, blocking of CGRP showed a simi-
lar efficacy with a reduction of monthly migraine days
from baseline of −2.9 (verum) vs. -1.8 (placebo) for ere-
numab (AMG-334) [43]; −4.3 (300 mg)/−3.9(100 mg) vs.
-3.2 (placebo) for eptinezumab (ALD-403), [41]; −4.0
(120 mg)/−3.8 (240 mg) vs. -2.15 (placebo) for galcane-
zumab (LY2951742) [40] and −3.7 (225 mg monthly)/
−3.4 (675 mg quarterly) vs. -2.2 (placebo) for fremanezu-
mab (TEV-48125) [42]. The ≥50% responder rates were
also significantly higher than for placebo and similar, al-
beit a little higher, to those of topiramate, ranging from
56.3% to 62.3% (≥50% responder rates: eptinezumab:
56.3% (300 mg)/ 49.8% (100 mg) vs. 37.4% (placebo)
[41]; galcanezumab: 62.3% (120 mg)/ 60.9% (120 mg) vs.
38.6% (placebo) [40]).
Topiramate has also proven efficacious in patients
with chronic migraine [47, 48]. In two randomized,
placebo-controlled, double-blinded studies with 387 sub-
jects with a daily dose of 100 mg or 50-200 mg topira-
mate showed a significant reduction in monthly
migraine days compared to placebo (−6.4 (±5.8) vs. -4.7
(±6.1) [47] and −3.5 (±6.3) vs. +0.2 (±4.7) [48]). The
≥50% responder rate was also significantly higher for
topiramate (22% vs. 0% for placebo) [48]. In line with
this, blocking of CGRP significantly reduced the number
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graine patients with an average of 19.4 headache days
(−4.8 (120 mg)/−4.6 (240 mg) vs. -2.7 (placebo)). Like-
wise, the ≥50% responder rate was significantly higher
for the active drug compared to placebo. (27.6%
(120 mg)/ 27.5% (240 mg) vs. 15.4%) [49].
Another important aspect of medication is the inci-
dence and severity of adverse events. Compared to topir-
amate, adverse events reported from CGRP trials were
generally mild and less frequent. Upper respiratory tract
infection/nasopharyngitis, and injection-site pain have so
far been the most frequent reported adverse events [40–
43] (see next paragraph for more details). In contrast,
reported adverse events of topiramate, such as taste
disturbance, weight loss, anorexia, fatigue, memory
problems and paresthesia were more common in the ac-
tive groups than in the placebo groups.
Safety issues regarding blocking of CGRP – Are
there any?
Evidence from clinical studies
Even though the knowledge of the presence and function
of CGRP in the CNS is sparse, the function in both the
peripheral and enteric nervous system is well established
and CGRP is expressed widely throughout both systems.
Thus, a wide variety of possible adverse events could be
anticipated when blocking CGRP. However, reported ad-
verse events after blocking of CGRP have in general been
mild to moderate and the incidences have been low.
Among the first CGRP receptor antagonists under
trial, intravenous olcegepant caused mild to moderate
adverse events such as paresthesia, nausea, headache,
dry mouth and unspecific vision disturbances in a mi-
nority of patients [18]. However, more serious adverse
events were reported with telcagepant and MK-3207,
which caused liver toxicity with transient increase of
transaminases in a small group of included subjects
(n = 13 for telcagepant) upon repeated doses. This lead
to discontinuation of the trial program for these mole-
cules [15, 25]. Other non-peptide CGRP receptor antag-
onists such as BI44370TA, BMS-927711, and, most
recently, MK-1602 have also been tested. For all three
molecules adverse events were mild to moderate and the
incidence was low and similar to the placebo group [21,
30, 33]. No liver toxicity was reported for these drugs,
and the gepant program is thus still ongoing.
More recently, great attention has been given to the de-
velopment and testing of monoclonal antibodies (mABs)
targeting circulating CGRP or its receptors. Most import-
antly, none of these drugs show liver toxicity. This is in
line with the theoretical probability of mABs causing liver
toxicity, which is very low, since metabolism of mABs do
not result in production of toxic metabolites [50]. In
addition, despite the potentially harmful inhibition ofvasodilation due to CGRP inhibition, no cardiovascular
concerns have been disclosed with any of these drugs [51].
In trials, eptinezumab, galcanezumab and fremanezumab,
monoclonal antibodies which all target CGRP, showed
variable percentages of adverse events, which in line with
the gepants, were mild to moderate (e.g. upper respiratory
or urinary tract infection, fatigue, back pain, arthralgia,
nausea and vomiting). Erenumab (AMG 334), which binds
to the CGRP receptor, was also safe and well tolerated in a
phase 2 trial [31].
In line with the poor chance of both the non-peptide
CGRP receptor antagonists and the antibodies crossing
the blood-brain barrier (BBB) [52], no central side effects
have been reported so far. Therefore, although crossing
of the BBB is likely to occur to some extent – telcage-
pant has been detected in primates cerebrospinal fluid,
suggesting its presence in the CNS [53] – a central effect
– and side effect – of these drugs seems unlikely.Do preclinical studies give reason to be concerned about
side effects?
CGRP is an ubiquitous peptide that is not only involved
in migraine, but also in several physiological processes
[12] and in homeostatic responses during pathophysio-
logical conditions (Fig. 3) [9, 12]. As such, it is vital to
consider the possible side effects caused by the non-
selective blockade of α- and β-CGRP with the CGRP (re-
ceptor)-antibodies. As discussed in the previous section,
the adverse events of the Phase II trials were mild [31,
32, 34–37], but it should be noted that the duration of
these trials is not sufficient to see the long-term effects
of continuingly blocking CGRP or its receptor.
In the cardiovascular system, CGRP is present in nerve
fibers that innervate blood vessels [54] and the heart [55,
56], and participates in the regulation of blood pressure
[12, 57–59]. Furthermore, it has also been described to
have a role in the maintenance of (cardio)vascular
homeostasis during ischemic events [9] and in tissue re-
modeling in pulmonary hypertension [60]. This protect-
ive role raises a concern, since migraine patients present
an increased cardiovascular risk [61, 62]. This topic was
recently reviewed elsewhere [9]. Hence, it is important
to consider preexisting cardiovascular risk factors in
patients (i.e. family history, tobacco exposure, obesity) to
prevent a possible cardiovascular event.
Although CGRP participates in inflammatory
processes [63–65], it has also been associated with facili-
tation of wound healing [66]. This is thought to be me-
diated through its ability to promote keratinocytes
proliferation [67], enhance revascularization [68], reduce
expression of tumor necrosis factor-α (TNF-α) and at-
tenuate macrophage infiltration [69]. A consequence of
blocking CGRP could thus be alterations in wound
Fig. 3 Possible side effects after long-term exposure to CGRP (receptor)-antibodies. An overview of the organ systems where CGRP and the recep-
tor are present and possible side effects that could be caused by the non-selective blockade of α- and β-CGRP with the
CGRP (receptor)-antibodies
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juries at the site of injection for the antibodies. However,
this is a theoretical risk which has so far not been ob-
served in clinical trials.
The antibodies against CGRP are not selective for α-
CGRP but also block β-CGRP. The gastrointestinal tract is
highly innervated by β-CGRPergic fibers from the enteric
nervous system [70, 71]. In fact, animal studies with anti-
bodies against CGRP showed extensive mucosal damage
[72, 73], suggesting a role of CGRP in maintaining the
mucosal integrity of the gastrointestinal tract. Blocking
this could thus contribute to inflammatory bowel disease.
Gastrointestinal motility is also considered to be modu-
lated by CGRP, and administration of this peptide induces
a dose-dependent biphasic response [74], which could lead
to episodes of diarrhea or constipation. Furthermore,
studies with CGRP KO mice have suggested CGRP ago-
nists as a possible treatment for ulcer healing [75]; there-
fore, monitoring of gastrointestinal complications (i.e.
ulcers, constipation) is recommended, even though
12 week studies have not reported these.
Finally, since it, as mentioned, is unlikely that the anti-
bodies cross the BBB – and unlikely that the BBB pene-
tration is changed during migraine attacks [76, 77] – it
is important to consider the structures from CNS that
are not protected by the BBB. Recent studies have dem-
onstrated that the TG, together with the pituitary, are
outside the BBB [78]. An effect on the TG could thus,partly, explain the therapeutic effect of the antibodies.
However, CGRP and its receptor are also expressed in
the anterior pituitary, suggesting a possible involvement
in the regulation of hypothalamo-pituitary tract func-
tions [79]. The exact involvement is still unknown, and
further studies are needed to determine the long-term
effects of blocking CGRP on the homeostatic functions
of the pituitary hormones.
Other considerations
Even though blocking of CGRP seems to be an effica-
cious and safe preventative treatment of migraine, there
are many other aspects to consider with regards to the
pros and cons of blocking CGRP in migraine patients.
Firstly, the administration of the newly developed
monoclonal antibodies is either intravenous or subcuta-
neous. This could potentially cause complications at the
injection site, and common adverse events in those
treated with fremanezumab, galcanezumab and erenu-
mab were indeed mild injection-site pain, pruritus and
erythema [80]. A disadvantage of the intravenous admin-
istration route is the need of it being administered by a
medical doctor. This not only increases the placebo re-
sponse in clinical trials, but does also require for the pa-
tient to spend time visiting the clinic – increasing the
risk of pathologization of the patient. However, the
monthly administration, which is feasible due to the long
half-lives of the medication, could improve adherence
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problem in treating migraine [81, 82]. Additionally, the
CGRP antibodies seem to show a low risk for drug-drug
interactions and hepatotoxicity since they are metabo-
lized by degradation into peptides and single amino
acids [83], which could be important for patients using
multiple medications.
Secondly, as mentioned, the long-term risks of block-
ing CGRP are still unknown. Even though the absence of
liver toxicity or other abnormalities in routine blood
testing is in support of no or low long-term risks [80],
studies testing the cardiovascular safety of the long-term
blockade are warranted in order to answer the numerous
questions on the possibility of higher risk in cardio- and
cerebrovascular compromised patients. For example, it is
unknown whether blocking CGRP could potentially
transform transient mild cerebral ischemia into a full-
blown brain infarct [9] and whether these risks are
higher in women [9, 84]. To investigate these aspects,
future studies should include patients with preexisting
cardiovascular conditions.
Thirdly, the exact site of action of blocking CGRP is
still partly unknown and CGRP could exert its effects on
receptors distinct from the CGRP receptor [9]. Recently
it was put forward that CGRP may act on the amylin re-
ceptor in TG [85] as well as in human coronary arteries
[86]. If this is the case, this could pose an additional –
unknown – potential risk of wiping out CGRP. We can
also only guess whether patients not benefitting from
receptor blockade would benefit from blockage of the
peptide itself. Future studies should investigate how to
differentiate responders from non-responders.
Lastly, a disadvantage when using antibodies is the risk
of development of antibodies against the drug [15]. In-
deed, antidrug antibodies were detected with all four anti-
bodies [80], but these did not seem to affect efficacy [31].
However, long-term studies are needed to investigate
whether, at long term, neutralizing antidrug antibodies will
pose a problem for efficacy and safety of blocking CGRP
with monoclonal antibodies. Finally, it is well known that
antibody treatment is costly and the price of the drugs has
to be taken into consideration when deciding whether to
use CGRP antibodies as a prophylactic treatment and
which patient groups to treat.
Conclusion
Here, we have reviewed the pros and cons of blocking
CGRP in migraine patients. In favor of using blocking of
CGRP as a treatment of migraine, is that – based on evi-
dence from clinical trials – whether using small molecule
receptor antagonists or antibodies, the treatment is effica-
cious. Additionally, the liver toxicity induced by some of
the gepants is not present with the antibodies, which are
well tolerated. Lastly, in contrast to current prophylactictreatments, the drugs are developed specifically for mi-
graine, based on findings from human migraine studies.
Thus, the drugs may exert a more direct effect on mi-
graine specific pathways than previously used prophylactic
drugs. In addition, this provides hope and encouragement
for further research into the pathophysiological mecha-
nisms of migraine and potentially the discovery of other
migraine specific therapeutic targets.
Speaking against chronically blocking CGRP, the long-
term effects, particularly regarding the cardiovascular risks,
are still unknown as well as the exact mode of action of the
antibodies. In addition, development of neutralizing antidrug
antibodies may, with time, affect the efficacy of the
antibodies. Lastly, as with all antibody therapies, CGRP anti-
bodies have the problem of being costly. However, taking
into consideration the enormous socioeconomically burden
that migraine is [87], the price may be well payed off.
In conclusion, based on current knowledge, we believe
that the benefits of blocking CGRP – including the
perspectives of improving the lives of those suffering
from frequent headaches – seems to be greater than the
disadvantages.
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